KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Asset Writedowns and Impairment (2023)

Inovio Pharmaceuticals (INO) has disclosed Asset Writedowns and Impairment for 1 consecutive years, with $2.0 million as the latest value for Q2 2023.

  • Quarterly Asset Writedowns and Impairment changed N/A to $2.0 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2024, changed 0.0% year-over-year, with the annual reading at $2.0 million for FY2023, N/A changed from the prior year.
  • Asset Writedowns and Impairment hit $2.0 million in Q2 2023 for Inovio Pharmaceuticals.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $2.0 million in Q2 2023 to a low of $2.0 million in Q2 2023.